Behind the growth figures lie questions that portfolio and strategy teams need to address. How fast will China move from asset supplier to global competitor? Are smaller, lower-risk pipelines enough to sustain long-term value? And as pricing dynamics shift, what will tomorrow’s most important payers actually reward?
The report covers:
- Worldwide prescription drug sales forecasts to 2032, including the top ten best-selling drugs and companies
- The therapy areas driving growth, and where competitive intensity is rising fastest
- How the second wave of the patent cliff is driving renewed M&A activity
- How China’s role in global pharma is evolving, and what that means for Western portfolio and dealmaking strategy
- What US pricing, policy, and regulatory turbulence means for pipeline construction and long-term commercial planning
